You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
大行評級 | 瑞銀:上調科濟藥業(2171.HK)目標價至58港元 評級“買入”
格隆匯9月28日丨瑞銀報告指出,科濟藥業(2171.HK)的CT041(一種靶向CLDN18.2自體CAR-T候選產品)在2021年歐洲腫瘤內科學會大會(ESMO)期間取得穩健成績,將其目標價由53港元上調至58港元,維持“買入”評級。該行指出,正在調整該藥對胃癌(GC)和胰腺癌(PC)適應症的預測成功概率(POS)。對於中國和美國的胃癌患者,該行將POS從50%增至55%;其他地區爲40%增至50%。至於胰腺癌患者,該行將歐盟、日本和韓國的POS從35%提高至40%。該股現報50港元,最新市值283億港元。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account